The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 25, 2020

Filed:

Nov. 30, 2016
Applicants:

Rutgers, the State University of New Jersey, New Brunswick, NJ (US);

Lehigh University, Bethlehem, PA (US);

Inventors:

Jeffrey D. Laskin, Piscataway, NJ (US);

Diane E. Heck, Rumson, NJ (US);

Mou-Tuan Huang, Piscataway, NJ (US);

Karine Fabio, La Gaude, FR;

Carl J. Lacey, New Tripoli, PA (US);

Sherri C. Young, Bloomsbury, NJ (US);

Pramod Mohanta, Bethlehem, NJ (US);

Christophe Guillon, Macungie, PA (US);

Ned D. Heindel, Easton, PA (US);

Assignees:

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, New Brunswick, NJ (US);

LEHIGH UNIVERSITY, Bethlehem, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07F 7/08 (2006.01); A61K 31/405 (2006.01); A61K 31/196 (2006.01); A61K 31/19 (2006.01); A61K 47/55 (2017.01); A61K 47/54 (2017.01); A61K 9/00 (2006.01); A61K 31/192 (2006.01); C07C 69/96 (2006.01); C07C 229/42 (2006.01); C07C 209/28 (2006.01); C07D 209/28 (2006.01);
U.S. Cl.
CPC ...
C07F 7/0812 (2013.01); A61K 9/0014 (2013.01); A61K 31/19 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/405 (2013.01); A61K 47/54 (2017.08); A61K 47/55 (2017.08); C07C 69/96 (2013.01); C07C 229/42 (2013.01); C07D 209/28 (2013.01); C07F 7/081 (2013.01); C07C 2602/10 (2017.05);
Abstract

A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X=C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.


Find Patent Forward Citations

Loading…